Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

76 Annual Financial Statement Konzern-Jahresabschluss
Interest
%
CeramOptec GmbH, Bonn / Germany (“CO”) 100
biolitec Sdn. Bhd., Kuala Lumpur / Malaysia (“biolitec Malaysia”)
– (wholy owned subsidiary of CO)
CeramOptec Ind. Inc., East Longmeadow, MA / USA (“CO USA”) 90
biolitec Inc., East Longmeadow, MA / USA (“biolitec USA”) 90
AndaOptec Ltd., Livani / Latvia (“AndaOptec”) 65.2
biolitec SIA, Riga / Latvia (“biolitec SIA“) 100
bioliprod GmbH, Jena / Germany (“bioliprod”)
Subsidiary of CO
GlycoSense AG, Jena / Germany (“GlycoSense”)
Subsidiary of CO
biolitec Italia SRL, Milano / Italy (“biolitec Italia”) 51
biolitec Pharma Marketing Ltd., Kuala Lumpur / Malaysia (“biolitec Marketing”) 100
Foscan Fund Management GmbH, Jena / Germany –
former biolitec Pharma GmbH (“Fund GmbH”, affiliate of bioliprod GmbH)
biolitec Pharma Ireland Ltd., Dublin / Ireland
– (“Pharma Ireland”, affiliate of biolitec Marketing)
biolitec KK, Tokyo / Japan (“biolitec Japan”) 80
biolitec India Private Ltd., Bangalore / India (“biolitec India”) 51
biolitec FZ LLC, Dubai Healthcare City / Dubai, United Arab Emirates (“biolitec Dubai“) 100
biolitec S.A., Buenos Aires / Argentina (“biolitec Argentina”) 95
biolitec Research GmbH, Jena / Germany (“biolitec Research“)
Subsidiary of CO
biolitec OOO, Saint Petersburg / Russia (“biolitec Russia“) 96
biolitec BCIE LTDA., Brazil (“biolitec Brazil”) 90
100
100
75
100
100
100